Prof. François Mach (h index >50), born in 1961, is an expert in the field of cardiology, in particular with regard to the development and progression of atherosclerosis diseases. After obtaining his MD at the University of Geneva, Switzerland, he studied internal medicine and cardiology at Geneva University Hospital. He then went on to complete a post-doctoral fellowship in the laboratory of Prof. Peter Libby, Brigham and Women’s Hospital, Boston (1995-1999). Following his return to Switzerland in 2000, he became full Professor of cardiology, and in 2006 he was appointed Head of the cardiology department at Geneva University Hospital. Between 2012-14, he was the President of the Swiss Society of Cardiology. François Mach is the author of more than 350 High Impact Factor publications, has obtained several European research grants (“European Vascular Genomics Network” [EVGN] FP6, “Inflammation and Vascular Wall Remodelling in Atherosclerosis” [AtheroRemo] FP7), and is currently involved in the Athero-B-Cell FP7 (Targeting and exploiting B cell function for treatment in cardiovascular disease, all funded by the European Community. As director of the cardiology basic science laboratory at the Faculty of the Medicine University of Geneva, Prof. François Mach and his research group have developed animal models of atherosclerosis, acute myocardial infarction, chronic myocardial ischemia, and ischemic stroke. During the last 10 years, the group of Prof. François Mach has substantially contributed to a better clarification of the inflammatory mechanisms underlying atherosclerosis and its acute dramatic complications, such as myocardial infarction and ischemic stroke, both in human cohorts and animal studies. For several years now, Prof. François Mach has also been strongly implicated in clinical research in the field of lipidology, by contributing to the design and completion of several clinical research projects and multi-center studies focussed on lipid-lowering agents, such as statins and, more recently, anti-PCSK9. In addition, he is also responsible for several Swiss cohorts of atherothrombotic patients and is one of the 3 co-chairs of the ESC 2019 Lipid Guidelines that will be published on September 1, 2019.
Athero-B-Cell FP7 (Targeting and exploiting B cell function for treatment in cardiovascular disease)
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
